Shots:

• Genovis to receive up front for an exclusive license to Xork & is eligible to receive development & sales-based milestones along with royalties on sales globally & holds the rights for research- preclinical- diagnostic & other non-therapeutic applications of Xork
• The collaboration will utilize Genovis’ IgG protease- IdeXork (Xork & Selecta’s ImmTOR platform for transformative gene therapies to treat patients with AAV immunity & IgG-mediated autoimmune diseases
• Selecta obtains an exclusive WW right to Xork. The combination of Xork & ImmTOR has the potential to mitigate pre-existing Abs to AAV- expand access to gene therapy- prevent de novo immunogenicity & enable re-dosing of Xork

 ­ | Ref: Globe Newswire | Image: Selectabio